Impact of wedelolactone in the anti‐glycation and anti‐diabetic activity in experimental diabetic animals

Abstract

The glycation reaction is the addition of free carbonyl group of reducing sugar to the free amino groups of proteins, lipoproteins and nucleic acids which results in the formation of an Amadori product which may ultimately lead to the generation of advanced glycation products (AGEs). The impact of AGEs on proteins consequently generates free radicals, "a key player" for the pathogenesis of diabetes mellitus. Gel electrophoresis was carried out to see the visual changes taking place as a result of the glycation reaction. In this study, the anti-glycation and anti-diabetic effect of wedelolactone (WED) was seen both in vitro and in vivo. WED reverted various biochemical markers in streptozotocin-induced diabetic rats along-with the improvements in the oxidative stress markers. It also decreased the levels of the glycated serum protein and fasting blood glucose. Broadly, WED not only inhibited glycation in vitro but also proved to be an effective in vivo anti-glycating agent. © 2018 IUBMB Life, 70(6):547-552, 2018.

Botanical Interventions to Improve Glucose Control and Options for Diabetes Therapy

“…Wedelolactone treatment (25 mg/kg/day, oral gavage) for 15 days in diabetic Wistar rats (STZ given at 70 mg/kg, single injection) reduced FBG and HbA1c, and improved circulating insulin and C-peptide levels. This intervention also attenuated the decline in plasma anti-oxidants GPx and CAT seen in diabetic control animals [193]. Wedelolactone also dampens the generation of AGEs [193], which are known to reduce insulin secretion and cause mitochondrial dysfunction and β-cell damage [196].…”

“…This intervention also attenuated the decline in plasma anti-oxidants GPx and CAT seen in diabetic control animals [193]. Wedelolactone also dampens the generation of AGEs [193], which are known to reduce insulin secretion and cause mitochondrial dysfunction and β-cell damage [196].…”

“…Wedelolactone, an organic chemical compound classified as a coumestan, was first isolated in 1956 from Eclipta alba, also known as a false daisy [192] (Table 3). Wedelolactone has been shown to reduce FBG and HbA1c levels in two chemically induced models of diabetes, STZ and alloxan [193,194]. Furthermore, wedelolactone has been shown to have anti-inflammatory actions in the islet in vivo and in vitro [195].…”

Antidiabetic Activity of Gold Nanoparticles Synthesized Using Wedelolactone in RIN-5F Cell Line

“…Previous studies also stated that DEHP impairs insulin-signaling and reduces the glycogen level in liver and adipose tissue by imparting insulin resistance and excess glycogenolysis [47,48]. On the contrary, WDL-AuNPs treatment showed the dose-dependent increase in glycogen level in liver of DEHP administered diabetic rats through improving the insulin level and, thereby, the glycogen storage in the liver [46].…”

“…As a result, there was elevated fasting blood glucose levels in DEHP treated rats. WDL-AuNPs administration dose-dependently reduced the fasting blood glucose level by nullifying the adverse effect of DEHP on pancreas and improving the insulin sensitivity in the target tissues through its anti-oxidant and free radicals scavenging activities [46]. Administration of WDL-AuNPs (40 mg/kg bw) was effective against the DEHP-induced hyperglycemia when compared to other doses WDL-AuNPs (10, 20 mg/kg bw) ( Table 2).…”